Análisis Farmacogenético en psiquiatría, estudio descriptivo de una experiencia clínica con 21 pacientes

Pharmacogenetic studies improve our understanding of the functional consequences of genetic variants, helping us to identify those patients predisposed to the occurrence of certain side effects, or those who will respond better to a specific s drug. We have conducted a descriptive study of 21 patients of whom 16 were admitted to the inpatient unit of the Psychiatry Service at the Hospital Ramon y Cajal in Madrid, and 5 in the psychiatric day hospital in the same center, who underwent the test Neurofarmagen (AB-Biotics), that search for genetic biomarkers in the DNA related either with good response, or intolerance, or variants in metabolization of 39 psychotropic drugs. Trying to identify once obtained the results, what percentage of patients were receiving optimal treatment, to each of the molecules identified in the test Neurofarmagen. Every one of the molecules were analyzed individually, and as a whole in its therapeutic group, differentiating 5 groups (antidepressants, antipsychotics, anticonvulsants, mood stabilizers, and miscellaneous). The intention to change treatment after a detailed analysis of the results, happened in 57.1% of the sample. We also identified in our sample, many patients who had at least a better treatment choice within the same therapeutic group, 81% were receiving suboptimal treatment, or had at least a probably better treatment option. Identifying these parameters before start a long treatment with our psychiatric patients, or to know a few days later once you have started, that there may be a better alternative, makes this genetic marker test a therapeutic tool too good to ignore it.